What we're reading, June 30, 2016: one doctor makes the case for the FDA moving away from a simple approval/no approval system; Massachusetts and Gilead come to an agreement over hepatitis C drug rebates; and Georgia considers Medicaid expansion.
In a commentary for The Wall Street Journal, cardiologist John Sotos, MD, makes the case for changing how the FDA approves drugs in the United States. He argues that the FDA should stop making decisions that are only approval or no approval and instead rate the drug’s safety, efficacy, and the degree of evidence supporting those 2 aspects. Taking such an approach would provide physicians and patients with a starting point when making decisions and it would allow drugs to reach the market faster, which could be life-changing and life-saving for patients with life-threatening diseases and no options.
Massachusetts and Gilead Sciences have come to an agreement over hepatitis C treatments. The state was threatening to sue the company over the cost of the drugs, but have reached a deal for the state to receive rebates fo most residents with the disease, reported STAT. The state is expected to save a significant amount of money under the deal where Gilead's Harvoni will be the exclusive therapy for 80% of the state's Medicaid program.
Georgia could following in Louisiana’s footsteps regarding Medicaid expansion. According to Kaiser Health News, after years of anti-expansion sentiment, Georgia is re-examining the possibility of expansion, possibly through a waiver plan. However, with 5 rural hospitals closing in Georgia since the beginning of 2013, access to care will remain an issue even if the state expands Medicaid coverage.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More